The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells

Molecular Cancer Therapeutics

Volumn 4, Issue 11, 2005, Pages 1740-1746

  Hsi, Linda C ^a   Xi, Xiaopei ^a   Wu, Yuanqing ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; 5 AZA 2' DEOXYCYTIDINE; ARACHIDONATE 15 LIPOXYGENASE; HYDROXY FATTY ACID; METHYLTRANSFERASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PREVENTION; CANCER THERAPY; CELL GROWTH; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG RESEARCH; ENZYME INDUCTION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONATE 15-LIPOXYGENASE; AZACITIDINE; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA FRAGMENTATION; DNA PRIMERS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; RNA, SMALL INTERFERING; TIME FACTORS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 28044450846     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0218     Document Type: Article

References (44)

1. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001;293:1068-70.
2. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
4. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
5. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-86.
6. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100: 2957-64.
7. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000;249: 135-64.
8. Momparler RL, Ayoub J. Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001;34 Suppl 4:S111-5.
9. Brown R, Plumb JA. Demethylation of DNA by decitabine in cancer chemotherapy. Expert Rev Anticancer Ther 2004;4:501-10.
10. Issa JP, Kantarjian H. Azacitidine. Nat Rev Drug Discov 2005;May Suppl:S6-7.
11. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62.
12. Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 2003;51: 231-9.
13. Lyons J, Bayar E, Fine G, et al. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs 2003;4:1442-50.
14. Issa JP. Decitabine. Curr Opin Oncol 2003;15:446-51.
15. Issa JP, Garcia-Monero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103:1635-40.
16. Ikawa H, Kamitani H, Calvo BF, Foley JF, Eling TE. Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res 1999;59: 360-6.
17. Shureiqi I, Wojno KJ, Poore JA, et al. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 1999;20:1985-95.
18. Shureiqi I, Chen D, Lee JJ, et al. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000;92:1136-42.
19. Hsi LC, Wilson L, Nixon J, Eling TE. 15-Lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor γ via the MAPK signaling pathway. J Biol Chem 2001;276:34545-52.
20. Kamitani H, Geller M, Eling TE. Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 1998;273:21569-77.
21. Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res 2004;64:8778-81.
22. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
23. Kelavkar U, Wang S, Montero A, Murtagh J, Shah K, Badr K. Human 15-lipoxygenase gene promoter: analysis and identification of DNA binding sites for IL-13-induced regulatory factors in monocytes. Mol Biol Rep 1998;25:173-82.
24. Tuma RS. Silencing the critics: new studies move closer to answering epigenetic questions. J Natl Cancer Inst 2004;96:1652-3.
25. Shureiqi I, Xu X, Chen D, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res 2001;61:4879-84.
26. Heslin MJ, Hawkins A, Boedefeld W, et al. Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann Surg 2005;24:941-6.
27. Wu J, Xia HH, Tu SP, et al. 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis 2003;24:243-7.
28. Shureiqi I, Jiang W, Fischer SM, et al. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res 2002;62:1178-83.
29. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ. Cell 1998;93:229-40.
30. Shureiqi I, Jiang W, Zou X, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cell. Proc Natl Acad Sci U S A 2003;100: 9968-73.
31. Herrmann JL, Menter DG, Beham A, von Eschenbach A, McDonnell TJ. Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. Exp Cell Res 1997; 234:442-51.
32. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4: 1046-52.
33. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95.
34. Gilbert J, Gore SD, Herman JG, Carducci MA. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clinical Cancer Res 2004;10:4589-96.
35. Wong J, Patterton D, Imhof A, Guschin D, Shi YB, Wolffe AP. Distinct requirements for chromatin assembly in transcriptional repression by thyroid hormone receptor and histone deacetylase. EMBO J 1998;17: 520-34.
36. Pederson DS, Morse RH. Effect of transcription of yeast chromatin on DNA topology in vivo. EMBO J 1990;9:1873-81.
37. Drabik CE, Nicita CA, Lutter LC. Measurement of the linking number change in transcribing chromatin. J Mol Biol 1997;267:794-806.
38. Lutter LC, Judis L, Paretti RF. Effects of histone acetylation on chromatin topology in vivo. Mol Cell Biol 1992;12:5004-14.
39. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
40. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19: 187-91.
41. Kass SU, Landsberger N, Wolffe AP. DNA methylation directs a time-dependent repression of transcription initiation. Curr Biol 1997;7: 157-65.
42. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
43. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
44. Kaslow DC, Migeon BR. DNA methylation stabilizes X chromosome inactivation in eutherians but not in marsupials: evidence for multistep maintenance of mammalian X dosage compensation. Proc Natl Acad Sci U S A 1987;84:6210-4.